Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success

Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success

Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist physicians, differentiating by indications is the key to success. Datamonitor has surveyed gastroenterologists, rheumatologists and dermatologists on attribute and brand perceptions

Scope

*Opinion from 540 physicians including rheumatologists, dermatologists and gastroenterologists

*Data from physicians and opinion leaders across the seven major markets of the US, Japan, France, Germany, Spain, Italy and the UK

*Analysis of the extent to which certain factors affect physician prescribing, with comparison across each specialty

*Analysis of the opinion dynamics for the key brands used across prominent autoimmune diseases

Highlights

Efficacy and safety factors will always be any physician's main consideration, drawing an average of 62% of the weighting by importance when prescribing a biologic therapy. Actemra's positive perception from rheumatologists, despite known side-effects, exemplifies the importance of informing physicians about issues, rather than masking them.

New TNF inhibitors in autoimmune disease battle against 'me-too' status and the strong positive opinion of the existing three products in the category. Humira leads the group with a total score 16% above the average. Newcomer anti-TNF options Simponi (golimumab) and Cimzia (certolizumab) are not well perceived by EU prescribing rheumatologists.

Dermatologists' exhibit cynicism towards biologic therapies, scoring all brands lower than other physician types, less surprising when considering the nature of most psoriasis therapies. However, Centocor's Stelara (ustekinumab) is highly anticipated with dermatologists scoring it 40% above average in terms of predicted efficacy.

Reasons to Purchase

*Target physicians more efficiently by understanding the differences in brand perception between physician specialties

*Tailor your marketing message to the attributes most important to prescribing physicians

*Assess the regional dynamics of physician perception in autoimmune disease across the seven major markets

04-Mar-09 PDF & SlidePack Pages: 137

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions